Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 10Withdrawn 2Not yet recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Lymphoma, Large B-Cell, Diffuse 6Prostatic Neoplasms 2Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Enteropathy-Associated T-Cell Lymphoma 1Autoimmune Diseases 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

polatuzumab vedotin 2glofitamab 2Prednisone 2Doxorubicin 2Cyclophosphamide 2relmacabtagene autoleucel 1obinutuzumab 1axicabtagene ciloleucel 1Rituximab 1Oxaliplatin 1Gemcitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Dendritic Cell Sarcoma, Interdigitating × Prednisone × Clear all
NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
134 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡